For example, intravitreal injection of the C3 inhibitor compstatin (POT‐4) injection, weekly for 6 months, resulted in drusen disappearance in a primate model with early onset macular degeneration,60 while a phase II study with the compstatin analogue (APL‐2, which is the PEGylated version of POT‐4; Apellis Pharmaceuticals) has shown a 29% significant reduction in geographic atrophy growth at 12 months in the monthly intravitreal injection group. The gene discussed is C3; the disease is atrophic macular degeneration.